Target intelligence / Profile preview

Magnesium transporter NIPA1 (NIPA1)

Target
NIPA1
Molecular classification
Transporter, Transmembrane protein, Solute carrier family (SLC57 subfamily)
01

Overview

Magnesium transporter NIPA1 (NIPA1) is a transmembrane protein belonging to the SLC57 family that encodes a magnesium ion transporter with 329 amino acids and nine transmembrane domains. The protein plays a crucial role in regulating cellular magnesium levels, localizes primarily to early endosomes and the plasma membrane in neuronal and epithelial cells, and shows regulated surface expression in response to extracellular magnesium concentrations. NIPA1 also interacts with the type II BMP receptor, inhibiting BMP signaling important for neural development and axonal maintenance. Mutations, particularly polyalanine expansions, in NIPA1 are causative for hereditary spastic paraplegia type 6 and may contribute to amyotrophic lateral sclerosis risk. Extensive evidence points to its importance in normal neurologic development and function, although its direct therapeutic targeting remains investigational.

Other names
Non-imprinted in Prader-Willi/Angelman syndrome region protein 1Spastic paraplegia 6 proteinSLC57A1FSP3SPG6MGC35570Spastic paraplegia type 6 protein
02

Mechanism of action

Not therapeutically exploited to date. Theoretical mechanisms could include modulation of magnesium transport, or pharmacologic inhibition/activation based on inhibitory effect on BMP signaling.

03

Biological functions

Magnesium ion transportRegulation of cellular magnesium homeostasisNervous system development and maintenanceInhibition of bone morphogenetic protein (BMP) signaling through interaction with type II BMP receptor and promotion of its endocytosis and lysosomal degradation
04

Disease associations

Neurodegenerative disease (especially hereditary spastic paraplegia type 6)Amyotrophic lateral sclerosis (ALS, risk factor)Neuropathy (peripheral, in complex SPG6)Potential roles in developmental syndromes associated with the Prader-Willi/Angelman region
05

Safety considerations

Loss of function or mutations lead to neurodegenerative disease (e.g., spastic paraplegia).Polyalanine expansions linked to risk of ALS and earlier onset.Potential developmental, neurologic, and metabolic effects due to alteration of magnesium homeostasis and BMP signaling.
06

Interacting drugs

No clinically established drugs that directly target NIPA1 are listed in current literature.

1 more in the full profile.

07

Biomarkers

Mutations (especially polyalanine repeat expansions) in NIPA1 for diagnosis of hereditary spastic paraplegia type 6 and risk prediction for ALS.Potential genetic biomarkers for spastic paraplegia phenotypes

Beyond the preview

Go deeper on Magnesium transporter NIPA1 (NIPA1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Magnesium transporter NIPA1 (NIPA1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call